Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model

Juhyun Song, Bo Eun Hur, Kiran Kumar Bokara, Wonsuk Yang, Hyun Jin Cho, Kyung Ah Park, Won Taek Lee, Kyoung Min Lee, Jong Eun Lee

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: Alzheimer's disease (AD) results in memory impairment and neuronal cell death in the brain. Previous studies demonstrated that intracerebroventricular administration of streptozotocin (STZ) induces pathological and behavioral alterations similar to those observed in AD. Agmatine (Agm) has been shown to exert neuroprotective effects in central nervous system disorders. In this study, we investigated whether Agm treatment could attenuate apoptosis and improve cognitive decline in a STZ-induced Alzheimer rat model. Materials and Methods: We studied the effect of Agm on AD pathology using a STZ-induced Alzheimer rat model. For each experiment, rats were given anesthesia (chloral hydrate 300 mg/kg, ip), followed by a single injection of STZ (1.5 mg/kg) bilaterally into each lateral ventricle (5 μL/ventricle). Rats were injected with Agm (100 mg/kg) daily up to two weeks from the surgery day. Results: Agm suppressed the accumulation of amyloid beta and enhanced insulin signal transduction in STZ-induced Alzheimer rats [experimetal control (EC) group]. Upon evaluation of cognitive function by Morris water maze testing, significant improvement of learning and memory dysfunction in the STZ-Agm group was observed compared with the EC group. Western blot results revealed significant attenuation of the protein expressions of cleaved caspase-3 and Bax, as well as increases in the protein expressions of Bcl2, PI3K, Nrf2, and γ-glutamyl cysteine synthetase, in the STZ-Agm group. Conclusion: Our results showed that Agm is involved in the activation of antioxidant signaling pathways and activation of insulin signal transduction. Accordingly, Agm may be a promising therapeutic agent for improving cognitive decline and attenuating apoptosis in AD.

Original languageEnglish
Pages (from-to)689-699
Number of pages11
JournalYonsei medical journal
Volume55
Issue number3
DOIs
Publication statusPublished - 2014 May

Fingerprint

Agmatine
Streptozocin
Cell Death
Alzheimer Disease
Signal Transduction
Insulin
Apoptosis
Chloral Hydrate
Cognitive Dysfunction
Control Groups
Lateral Ventricles
Central Nervous System Diseases
Neuroprotective Agents
Ligases
Ambulatory Surgical Procedures
Phosphatidylinositol 3-Kinases
Amyloid
Caspase 3
Cognition
Cysteine

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Song, Juhyun ; Hur, Bo Eun ; Bokara, Kiran Kumar ; Yang, Wonsuk ; Cho, Hyun Jin ; Park, Kyung Ah ; Lee, Won Taek ; Lee, Kyoung Min ; Lee, Jong Eun. / Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. In: Yonsei medical journal. 2014 ; Vol. 55, No. 3. pp. 689-699.
@article{2689472ea50044bcbb00794fbc4d267e,
title = "Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model",
abstract = "Purpose: Alzheimer's disease (AD) results in memory impairment and neuronal cell death in the brain. Previous studies demonstrated that intracerebroventricular administration of streptozotocin (STZ) induces pathological and behavioral alterations similar to those observed in AD. Agmatine (Agm) has been shown to exert neuroprotective effects in central nervous system disorders. In this study, we investigated whether Agm treatment could attenuate apoptosis and improve cognitive decline in a STZ-induced Alzheimer rat model. Materials and Methods: We studied the effect of Agm on AD pathology using a STZ-induced Alzheimer rat model. For each experiment, rats were given anesthesia (chloral hydrate 300 mg/kg, ip), followed by a single injection of STZ (1.5 mg/kg) bilaterally into each lateral ventricle (5 μL/ventricle). Rats were injected with Agm (100 mg/kg) daily up to two weeks from the surgery day. Results: Agm suppressed the accumulation of amyloid beta and enhanced insulin signal transduction in STZ-induced Alzheimer rats [experimetal control (EC) group]. Upon evaluation of cognitive function by Morris water maze testing, significant improvement of learning and memory dysfunction in the STZ-Agm group was observed compared with the EC group. Western blot results revealed significant attenuation of the protein expressions of cleaved caspase-3 and Bax, as well as increases in the protein expressions of Bcl2, PI3K, Nrf2, and γ-glutamyl cysteine synthetase, in the STZ-Agm group. Conclusion: Our results showed that Agm is involved in the activation of antioxidant signaling pathways and activation of insulin signal transduction. Accordingly, Agm may be a promising therapeutic agent for improving cognitive decline and attenuating apoptosis in AD.",
author = "Juhyun Song and Hur, {Bo Eun} and Bokara, {Kiran Kumar} and Wonsuk Yang and Cho, {Hyun Jin} and Park, {Kyung Ah} and Lee, {Won Taek} and Lee, {Kyoung Min} and Lee, {Jong Eun}",
year = "2014",
month = "5",
doi = "10.3349/ymj.2014.55.3.689",
language = "English",
volume = "55",
pages = "689--699",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model. / Song, Juhyun; Hur, Bo Eun; Bokara, Kiran Kumar; Yang, Wonsuk; Cho, Hyun Jin; Park, Kyung Ah; Lee, Won Taek; Lee, Kyoung Min; Lee, Jong Eun.

In: Yonsei medical journal, Vol. 55, No. 3, 05.2014, p. 689-699.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Agmatine improves cognitive dysfunction and prevents cell death in a streptozotocin-induced Alzheimer rat model

AU - Song, Juhyun

AU - Hur, Bo Eun

AU - Bokara, Kiran Kumar

AU - Yang, Wonsuk

AU - Cho, Hyun Jin

AU - Park, Kyung Ah

AU - Lee, Won Taek

AU - Lee, Kyoung Min

AU - Lee, Jong Eun

PY - 2014/5

Y1 - 2014/5

N2 - Purpose: Alzheimer's disease (AD) results in memory impairment and neuronal cell death in the brain. Previous studies demonstrated that intracerebroventricular administration of streptozotocin (STZ) induces pathological and behavioral alterations similar to those observed in AD. Agmatine (Agm) has been shown to exert neuroprotective effects in central nervous system disorders. In this study, we investigated whether Agm treatment could attenuate apoptosis and improve cognitive decline in a STZ-induced Alzheimer rat model. Materials and Methods: We studied the effect of Agm on AD pathology using a STZ-induced Alzheimer rat model. For each experiment, rats were given anesthesia (chloral hydrate 300 mg/kg, ip), followed by a single injection of STZ (1.5 mg/kg) bilaterally into each lateral ventricle (5 μL/ventricle). Rats were injected with Agm (100 mg/kg) daily up to two weeks from the surgery day. Results: Agm suppressed the accumulation of amyloid beta and enhanced insulin signal transduction in STZ-induced Alzheimer rats [experimetal control (EC) group]. Upon evaluation of cognitive function by Morris water maze testing, significant improvement of learning and memory dysfunction in the STZ-Agm group was observed compared with the EC group. Western blot results revealed significant attenuation of the protein expressions of cleaved caspase-3 and Bax, as well as increases in the protein expressions of Bcl2, PI3K, Nrf2, and γ-glutamyl cysteine synthetase, in the STZ-Agm group. Conclusion: Our results showed that Agm is involved in the activation of antioxidant signaling pathways and activation of insulin signal transduction. Accordingly, Agm may be a promising therapeutic agent for improving cognitive decline and attenuating apoptosis in AD.

AB - Purpose: Alzheimer's disease (AD) results in memory impairment and neuronal cell death in the brain. Previous studies demonstrated that intracerebroventricular administration of streptozotocin (STZ) induces pathological and behavioral alterations similar to those observed in AD. Agmatine (Agm) has been shown to exert neuroprotective effects in central nervous system disorders. In this study, we investigated whether Agm treatment could attenuate apoptosis and improve cognitive decline in a STZ-induced Alzheimer rat model. Materials and Methods: We studied the effect of Agm on AD pathology using a STZ-induced Alzheimer rat model. For each experiment, rats were given anesthesia (chloral hydrate 300 mg/kg, ip), followed by a single injection of STZ (1.5 mg/kg) bilaterally into each lateral ventricle (5 μL/ventricle). Rats were injected with Agm (100 mg/kg) daily up to two weeks from the surgery day. Results: Agm suppressed the accumulation of amyloid beta and enhanced insulin signal transduction in STZ-induced Alzheimer rats [experimetal control (EC) group]. Upon evaluation of cognitive function by Morris water maze testing, significant improvement of learning and memory dysfunction in the STZ-Agm group was observed compared with the EC group. Western blot results revealed significant attenuation of the protein expressions of cleaved caspase-3 and Bax, as well as increases in the protein expressions of Bcl2, PI3K, Nrf2, and γ-glutamyl cysteine synthetase, in the STZ-Agm group. Conclusion: Our results showed that Agm is involved in the activation of antioxidant signaling pathways and activation of insulin signal transduction. Accordingly, Agm may be a promising therapeutic agent for improving cognitive decline and attenuating apoptosis in AD.

UR - http://www.scopus.com/inward/record.url?scp=84898767511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898767511&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.3.689

DO - 10.3349/ymj.2014.55.3.689

M3 - Article

C2 - 24719136

AN - SCOPUS:84898767511

VL - 55

SP - 689

EP - 699

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -